OmniAb, the antibody division of Ligand Pharmaceuticals, is set to go public through a SPAC merger that will infuse the business with up to $266 million. The deal comes as traditional IPOs have mostly ground to a halt due to uncertain market conditions, but Ligand is making a longer-term bet on growing demand for antibody drug discovery services.
Ligand Pharmaceuticals has turned a series of antibody discovery acquisitions into a growing business unit. Ligand now wants to spin it off as a separate company, but that new company will compete head to head against established antibody players AbCellera and Adimab.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
This acquisition is a logical fit for Ligand, as OMT will add a slew of monoclonal antibody therapeutics to its small molecule-dominant pipeline.
A San Diego biotech startup focused on treating metabolic and endocrine disorders has picked up a portfolio of drug candidates and a $2.5 million investment from Ligand Pharmaceuticals (NASDAQ:LGND). Viking Therapeutics said it’s licensed five programs from Ligand, including a Phase 2 program aimed at type 2 diabetes and another at wasting syndrome in cancer. […]
A GlaxoSmithKline orphan drug developed to treat a rare blood disorder characterized by a low number of platelets in the blood now has full U.S. Food and Drug Administration approval.